CAJ | 학술논문

目的探讨肝动脉化疗栓塞术(TACE)对原发性肝癌(HCC)根治术后抗复发作用.方法回顾性收集2008年1月至2009年7月间HCC根治术后未接受预防性TACE的患者40例(对照组)和术后接受一次预防性TACE 的患者27例(治疗组),治疗组患者在术后1-2月给予一次预防性TACE.全部病例在根治术后随访36-40个月,对比分析两组间的累计复发率.结果 HCC根治术后,对照组1,2,3年累计复发率分别为57.5﹪,65.0﹪,67.5﹪;治疗组1,2,3年累计复发率分别为29.6﹪,33.3﹪,33.3﹪.统计学分析治疗组1、2、3年复发率均明显低于对照组(P=0.019、P=0.012、P=0.008).治疗组TACE术后反应较轻,患者均可耐受,未出现严重并发症.结论 HCC根治术后给予一次预防性TACE在临床应用上是可行、安全、有效的,可明显降低术后复发率.
목적탐토간동맥화료전새술(TACE)대원발성간암(HCC)근치술후항복발작용.방법회고성수집2008년1월지2009년7월간HCC근치술후미접수예방성TACE적환자40례(대조조)화술후접수일차예방성TACE 적환자27례(치료조),치료조환자재술후1-2월급여일차예방성TACE.전부병례재근치술후수방36-40개월,대비분석량조간적루계복발솔.결과 HCC근치술후,대조조1,2,3년루계복발솔분별위57.5﹪,65.0﹪,67.5﹪;치료조1,2,3년루계복발솔분별위29.6﹪,33.3﹪,33.3﹪.통계학분석치료조1、2、3년복발솔균명현저우대조조(P=0.019、P=0.012、P=0.008).치료조TACE술후반응교경,환자균가내수,미출현엄중병발증.결론 HCC근치술후급여일차예방성TACE재림상응용상시가행、안전、유효적,가명현강저술후복발솔.
Objective To explore the clinical efficacy of transcatheter arterial chemoembolization (TACE) on preventing postoperative recurrence of hepatocelular carcinoma. Methods A total of consecutive 67 postopetative patients with hepatocelular carcinoma(HCC) from January 2008 to July 2009 were colected retrospectively.The patients were divided into two groups according receiving TACE or not:the control group (n=40) with operation only and the study group (n=27) with receiving one prophylactic TACE at 1-2 months after operation. Al cases were folowed up for 36 to 40 months after surgery. The rates of cumulative recurrence between two groups was compared. Results The 1- , 2- and 3-year cumulative recurrent rates in control group were 57.5﹪、65.0﹪、67.5﹪ respectively, while as were29.6﹪ ,33.3﹪ ,33.3﹪ in the study group,respectively. Statistical analysis showed that relapse rate was lower in the control group than in the study group in 1, 2, 3 years(P=0.019、P=0.012、P=0.008). Liver function damage of al patients in the study group were minimal after TACE and no serious complications occurred. Conclusion For hepatocelular carcinoma patients, receiving one preventative TACE at 1-2 months after hepatectomy is safe and effective to decrease significantly the postoperative recurrence rates.